New treatment for certain blood cancers using engineered T cells
CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms
This study is testing a new treatment that uses specially modified immune cells to help patients with certain types of blood cancers, like lymphoma and leukemia, especially those who haven't had success with regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10873663 on NIH RePORTER |
What this research studies
This research investigates a novel therapy using genetically modified T cells to target and treat patients with CD4 positive T cell malignancies, such as lymphoma and leukemia. The therapy involves creating autologous T cells that are engineered to recognize and attack cancer cells expressing CD4. Patients will undergo a preparatory chemotherapy regimen before receiving the modified T cells, which will be administered in a controlled hospital setting. The study aims to assess the safety and feasibility of this treatment approach in patients who have not responded to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates are patients with relapsed or refractory CD4 positive T cell lymphoma or leukemia who have not responded to second-line standard therapies.
Not a fit: Patients with CD4 positive malignancies who are not heavily pretreated or those who have not failed previous therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with difficult-to-treat CD4 positive blood cancers.
How similar studies have performed: Similar approaches using engineered T cell therapies have shown promise in treating various blood cancers, indicating potential for success in this novel application.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Salman, Huda — Indiana University Indianapolis
- Study coordinator: Salman, Huda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.